Active Not RecruitingNCT05310695
Official study titleA Multicentre Randomised Controlled Trial of the Norwegian Health in Work Service for Patients With Common Mental Disorders and Musculoskeletal Disorders: The Norwegian Sickness Absence Clinic (NSAC) Efficacy Study
This study is no longer accepting new participants.
Multiple locations, including BodøAnxiety, DepressionInterventional studyAges 18+
- Countries
- Norway
- Sponsor
- Nordlandssykehuset HF
CompletedEUCTR 2020-001348-25
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In Czech RepublicDepressionHistorical research record
- Countries
- Czechia, Denmark, Germany, + 2 others
- Sponsor
- COMPASS Pathways, Ltd
CompletedEUCTR 2017-004602-17
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In United KingdomSchizophreniaHistorical research record
- Countries
- United Kingdom
- Sponsor
- Otsuka Pharmaceutical
CompletedEUCTR 2018-001963-22
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In PolandDepression, BipolarityHistorical research record
- Countries
- Poland
- Sponsor
- Celon Pharma SA
CompletedEUCTR 2018-002669-20
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In PolandBipolarity, DepressionHistorical research record
- Countries
- Poland
- Sponsor
- Celon Pharma SA
CompletedACTRN12618001048279
Official study titleA Multicentre, Open-Label, Phase 2 Safety Extension Study to Evaluate the Safety and Tolerability of R-107 in subjects with Refractory Major Depressive Disorder.
This study has finished and is no longer accepting participants.
Multiple locations, including SouthportDepressionInterventional studyAges 18–81
- Countries
- Australia, New Zealand
- Sponsor
- Douglas Pharmaceuticals Ltd.
CompletedEUCTR 2004-000730-37
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In Czech RepublicADHDHistorical research record
- Countries
- Czechia, Denmark, Finland, + 1 other
- Sponsor
- Janssen-Cilag Medical Affairs EMEA
CompletedNCT05391698
Official study titleDeterminants of Treatment Response to State-of-the-art Interventions for Attention Deficits: Child Temperament, Cognitive Profiles and Family Dynamics
This study has finished and is no longer accepting participants.
In RethymnoADHDBehavioural studyAges 9–12
- Countries
- Greece
- Sponsor
- University of Crete
CompletedNCT03126526
Official study titleTargeting Top-down and Bottom-up Processing in Eating Disorders Using Computerized Training Approaches: A Multimodal Outcome Study
This study has finished and is no longer accepting participants.
In LondonEating disordersBehavioural studyAges 18–60
- Countries
- United Kingdom
- Sponsor
- King's College London (University)
CompletedEUCTR 2022-001865-11
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In BulgariaSchizophreniaHistorical research record
- Countries
- Bulgaria
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
CompletedEUCTR 2010-022257-41
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In FinlandDepressionHistorical research record
- Countries
- Finland, Germany, Latvia, + 1 other
- Sponsor
- Takeda Global Research and Development Centre (Europe) Ltd.
CompletedNCT04136873
What is this study about?This study evaluated the safety of CVL-231 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including BentonvilleSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- Cerevel Therapeutics, LLC